Involvement of naïve T cells in the pathogenesis of osimertinib-induced pneumonitis

Abstract Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, effectively treats EGFR-mutated non-small cell lung cancer. Drug-induced interstitial lung disease, a potentially fatal complication of osimertinib, involves an increase in lymphocytes in the...

詳細記述

書誌詳細

出版年:	Scientific Reports
主要な著者:	Hiroyuki Ando, Kazuya Tsubouchi, Toyoshi Yanagihara, Kentaro Hata, Daisuke Eto, Kunihiro Suzuki, Naoki Hamada, Isamu Okamoto
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2025-03-01
主題:	Osimertinib Pneumonitis Naïve T cells Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) CCL21
オンライン･アクセス:	https://doi.org/10.1038/s41598-025-95271-9